Scarica l'app Stockscreener
63.24
1.93%
1.20
Dopo l'orario di chiusura:
63.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$62.04
Aprire:
$62.78
Volume 24 ore:
882.03K
Relative Volume:
0.48
Capitalizzazione di mercato:
$7.46B
Reddito:
$1.40B
Utile/perdita netta:
$316.89M
Rapporto P/E:
25.38
EPS:
2.4918
Flusso di cassa netto:
$644.59M
1 W Prestazione:
-0.64%
1M Prestazione:
-10.11%
6M Prestazione:
-14.51%
1 anno Prestazione:
-2.47%
Intervallo 1D:
$62.69
$63.62
Intervallo di 1 settimana:
$61.49
$65.11
Portata 52W:
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
63.24 | 7.32B | 1.40B | 316.89M | 644.59M | 2.4918 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Downgrade | Goldman | Neutral → Sell |
| 2025-10-14 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Why is Halozyme Therapeutics (HALO) down 13.1% since last earnings report? - MSN
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks - TradingView
Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance - MSN
Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics - National Today
Congress Asset Management Co. Cuts Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Interim CFO at Halozyme (NASDAQ: HALO) files initial Form 3 ownership - Stock Titan
HALOZYME THERAPEUTICS, INC. ($HALO) President and CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] HALOZYME THERAPEUTICS, INC.... | HALO SEC FilingForm ARS - Stock Titan
Executive pay, board elections lead Halozyme (NASDAQ: HALO) 2026 proxy - Stock Titan
Halozyme appoints David Ramsay as interim CFO - MSN
Moving Averages: Will Halozyme Therapeutics Inc benefit from seasonality2026 Buyback Activity & Proven Capital Preservation Methods - baoquankhu1.vn
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Allworth Financial LP - MarketBeat
Halozyme Touts $1.8B Revenue Outlook, Expanding Subcutaneous Drug Delivery - National Today
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - GlobeNewswire Inc.
What Has Caused Halozyme Therapeutics (HALO) Shares to Fall 13.1% Following Its Most Recent Earnings Report? - Bitget
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report? - Yahoo Finance
Halozyme Therapeutics : ESG Key Data & Metrics (rev11 Halozyme ESG Key Data 2026 ISS Corporate comments Mar2026 version 1 for publication) - marketscreener.com
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference - MarketBeat
Alliancebernstein Reduces Stake in Halozyme Therapeutics - National Today
Alliancebernstein L.P. Trims Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Could Halozyme (HALO) Returning David Ramsay as Interim CFO Reframe Its ENHANZE Royalty Story? - simplywall.st
Growth Value: Is Halozyme Therapeutics Inc forming a bullish divergenceWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Clark Capital Management Group Inc. - MarketBeat
Brevan Howard Sells Stake in Halozyme Therapeutics - National Today
Brevan Howard Capital Management LP Sells 96,806 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Aquatic Capital Management Buys Stake in Halozyme Therapeutics - National Today
Aquatic Capital Management LLC Acquires Shares of 89,651 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. $HALO Shares Bought by ArrowMark Colorado Holdings LLC - MarketBeat
Halozyme names David Ramsay as interim CFO - Investing.com Nigeria
Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback - Sahm
Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility - simplywall.st
Halozyme Therapeutics Receives 'Hold' Rating from Analysts - National Today
2Xideas AG Trims Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness - Yahoo Finance
Kennedy Capital Management LLC Reduces Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Appoints David Ramsay as Interim Chief Financial Officer - Sahm
Halozyme names David Ramsay as interim CFO By Investing.com - Investing.com India
Halozyme Taps David Ramsay as Interim Chief Financial Officer - Contract Pharma
Is Halozyme Therapeutics a Better Buy Than United Therapeutics? - Trefis
Halozyme Names David Ramsay Interim Chief Financial Officer - TipRanks
Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 - marketscreener.com
Halozyme (HALO) Appoints David Ramsay as Interim CFO - GuruFocus
Halozyme (HALO) Appoints Interim CFO Amid Search for Permanent E - GuruFocus
David Ramsay returns as interim CFO at Halozyme (HALO) - Stock Titan
Capital Fund Management Boosts Stake in Halozyme Therapeutics - National Today
Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):